Amifostine Attenuates Doxorubicin-Induced Subacute Hepatic and Renal Toxicity in Rats
International Journal of Molecular Sciences · 19.07.2026 · 27 (14) · 6419
DOI: 10.3390/ijms27146419 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.07.2026. Verfasst von Vesna Jaćević und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Toxicology and Pharmacology, National Poison Control Centre, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Ser…. Hauptthemen laut MEDLINE: Doxorubicin, Amifostine, Kidney, Liver. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aimed to evaluate the general, hepatoprotective and renoprotective effects of amifostine (AMI) in rats treated with a large, single dose of doxorubicin (DOX), assessed at 7 and 56 days after administration. Rats were divided into six experimental groups: Control (0.9% NaCl intraperitoneally (ip)), amifostine (AMI300, 300 mg/kg (ip)), doxorubicin (DOX6, 6 mg/kg (ip)), doxorubicin (DOX10, 10 mg/kg (ip)), doxorubicin (DOX6, 6 mg/kg (ip)) + amifostine (AMI300, 300 mg/kg (ip) 30 min before DOX6), and doxorubicin (DOX10, 10 mg/kg (ip)) + amifostine (AMI300, 300 mg/kg (ip) 30 min before DOX10). Absolute liver and kidney weights were significantly increased in AMI300 + DOX6-treated animals compared to DOX6 only on day 56. In the group of DOX10-treated rats, AMI300 significantly prevented changes in the number of white blood cells during the four weeks after treatment. The severity of hepatic and renal injuries in the DOX6-treated groups was also significantly less in rats pretreated with AMI300 on day 56 (p < 0.01). Our results indicate that hepatic and renal protection significantly contribute to the successful use of AMI against DOX-induced subacute toxicity in rats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Toxicology and Pharmacology, National Poison Control Centre, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia.
- Department for Pharmacological Science, Medical Faculty of the Military Medical Academy, University of Defence in Belgrade, Crnotravska 17, 11000 Belgrade, Serbia.
- Centre for Clinical Pharmacology, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia.
- Department of Cardiovascular Research, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, 11129 Belgrade, Serbia.
- Vojnosanitetski Pregled, Medical Faculty of the Military Medical Academy, University of Defence in Belgrade, Crnotravska 17, 11000 Belgrade, Serbia.
- Special Police Unit, Police Department of the City of Belgrade, Ministry of Interior, Trebevićka 12/A, 11030 Belgrade, Serbia.
ORCID-Profile: Vesna Jaćević, Viktorija Dragojević-Simić, Jelica Grujić-Milanović, Silva Dobrić, Sladjan Milanović, Radoje Simić
Zitieren
APA
Jaćević, V., Dragojević-Simić, V., Grujić-Milanović, J., Dobrić, S., Bokonjić, D., Milovanović, Z., Milanović, S., & Simić, R. (2026). Amifostine Attenuates Doxorubicin-Induced Subacute Hepatic and Renal Toxicity in Rats. International Journal of Molecular Sciences, 27(14), 6419. https://doi.org/10.3390/ijms27146419
Vancouver
Jaćević V, Dragojević-Simić V, Grujić-Milanović J, Dobrić S, Bokonjić D, Milovanović Z, et al. Amifostine Attenuates Doxorubicin-Induced Subacute Hepatic and Renal Toxicity in Rats. International Journal of Molecular Sciences. 2026;27(14):6419. doi:10.3390/ijms27146419
BibTeX
@article{Jaevi2026,
author = {Jaćević, Vesna and Dragojević-Simić, Viktorija and Grujić-Milanović, Jelica and Dobrić, Silva and Bokonjić, Dubravko and Milovanović, Zoran and Milanović, Sladjan and Simić, Radoje},
title = {Amifostine Attenuates Doxorubicin-Induced Subacute Hepatic and Renal Toxicity in Rats},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {14},
pages = {6419},
doi = {10.3390/ijms27146419}
}
EUVIMED